NRX Pharmaceuticals Inc.(NRXP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NRXP NRX Pharmaceuticals Inc.

未开盘 07-27 16:00:00 EDT

3.63

-0.12

-3.20%

盘后3.70

+0.07+1.93%

19:59 EDT

最高3.89	最低3.57	成交量96.00万
今开3.81	昨收3.75	日振幅8.53%
总市值1.52亿	流通市值1.31亿	总股本4,194万
成交额355.14万	换手率2.65%	流通股本3,620万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":3.63,"timestamp":1785182400000,"preClose":3.75,"halted":0,"volume":959953,"hourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.63,"latestTime":"19:59 EDT","volume":34856,"amount":126018.55,"timestamp":1785196741625,"change":0.07,"changeRate":0.019284,"amplitude":0.027548},"delay":0,"changeRate":-0.03200000000000003,"floatShares":36197200,"shares":41943300,"eps":-0.966884,"marketStatus":"未开盘","change":-0.12,"latestTime":"07-27 16:00:00 EDT","open":3.81,"high":3.89,"low":3.57,"amount":3551377.3219725,"amplitude":0.085333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.966884,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785225600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":3.75,"preHourTrading":{"tag":"盘前","latestPrice":3.8,"preClose":3.75,"latestTime":"09:29 EDT","volume":46642,"amount":180805.334258,"timestamp":1785158999999,"change":0.05,"changeRate":0.013333,"amplitude":0.061333},"postHourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.63,"latestTime":"19:59 EDT","volume":34856,"amount":126018.55,"timestamp":1785196741625,"change":0.07,"changeRate":0.019284,"amplitude":0.027548},"volumeRatio":1.353277,"impliedVol":2.4544,"impliedVolPercentile":0.9124},"requestUrl":"/m/hq/s/NRXP","defaultTab":"news","newsList":[{"id":"1154218602","title":"NRX Pharmaceuticals：公司认为收购或放弃任何单一诊所对Hope整体商业模式均不构成重大影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1154218602","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154218602?lang=zh_cn&edition=full","pubTime":"2026-06-26 04:03","pubTimestamp":1782417795,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. 表示，无论收购还是放弃任何一家独立诊所，公司均不认为这会对“Hope”项目的整体商业模式产生实质性影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106163346","title":"NRX Pharmaceuticals子公司Hope Therapeutics采用Zeta Surgical经FDA批准的Zeta TMS导航系统完成首批患者治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1106163346","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106163346?lang=zh_cn&edition=full","pubTime":"2026-06-25 19:02","pubTimestamp":1782385357,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals旗下子公司Hope Therapeutics已成功运用Zeta Surgical公司获得美国食品药品监督管理局（FDA）批准的Zeta TMS导航系统，为首批患者提供了治疗。这一进展标志着该创新技术在临床实践中的初步应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159214495","title":"Kadima神经精神病学研究所：诉讼寻求法院判令强制被告按已签署协议条款完成交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1159214495","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159214495?lang=zh_cn&edition=full","pubTime":"2026-06-25 01:21","pubTimestamp":1782321694,"startTime":"0","endTime":"0","summary":"Kadima神经精神病学研究所已向法院提起诉讼，要求强制被告方履行已签署协议中的条款并完成交易。该诉讼旨在通过法律途径寻求特定履行，即要求法院下达命令，迫使被告方按照双方先前达成的协议内容，执行并完成相关交易。此举凸显了协议执行过程中出现的争议，并试图通过司法干预确保合约义务得到落实。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198462253","title":"Zeta Surgical® 宣布在Hope Therapeutics成功使用Zeta Tms导航系统完成首例患者治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1198462253","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198462253?lang=zh_cn&edition=full","pubTime":"2026-06-23 23:06","pubTimestamp":1782227178,"startTime":"0","endTime":"0","summary":"Zeta Surgical® 宣布，其Zeta Tms导航系统在Hope Therapeutics成功完成了首例患者的临床治疗。这一里程碑标志着该导航系统在临床应用上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161710155","title":"NRX Pharmaceuticals宣布FDA批准扩大使用协议，将D-环丝氨酸为基础的NRX-101用于增强经颅磁刺激治疗抑郁症","url":"https://stock-news.laohu8.com/highlight/detail?id=1161710155","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161710155?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:03","pubTimestamp":1782126201,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals宣布，美国食品药品监督管理局（FDA）已批准一项扩大使用协议，允许将基于D-环丝氨酸的NRX-101药物，作为经颅磁刺激治疗抑郁症方案的增强剂。\n这项协议意味着，符合条件的患者将能够提前获得这种尚在临床研究阶段的治疗组合。NRX-101是一种口服药物，旨在增强经颅磁刺激的神经可塑性效应，从而可能为对现有疗法反应不佳的抑郁症患者提供新的希望。\n扩大使用协议通常适用于患有严重或危及生命疾病的患者，且当没有可比或令人满意的替代疗法时。此举为部分患者提供了在药物正式获批上市前接受潜在有效治疗的途径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142463221","title":"NRX Pharmaceuticals Inc.完成2230万美元普通股公开发行，包销商期权获全额行使","url":"https://stock-news.laohu8.com/highlight/detail?id=1142463221","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142463221?lang=zh_cn&edition=full","pubTime":"2026-06-05 05:13","pubTimestamp":1780607593,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. 宣布，其普通股公开发行已成功完成，募集资金总额达2230万美元。此次发行包含了包销商期权的全额行使。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120213361","title":"NRX制药公司公布2026年第一季度财务业绩及企业动态更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1120213361","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120213361?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:00","pubTimestamp":1779102044,"startTime":"0","endTime":"0","summary":"NRX制药公司（纳斯达克股票代码：NRXP）近日发布了其2026年第一季度的财务报告，并同步更新了公司近期的运营进展。\n公司管理层在报告中详细阐述了本季度的财务状况，包括收入、支出及研发投入等关键财务指标。与此同时，公告也涵盖了公司在核心药物研发管线、临床试验进度以及未来战略规划方面的最新信息。这些更新旨在向投资者全面展示公司在报告期内的经营成果与未来发展蓝图。\n财务业绩的披露为企业评估自身运营效率与资金状况提供了依据，而公司动态的分享则有助于市场了解其在产品开发与商业化道路上的具体步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193230332","title":"NRX Pharmaceuticals Inc. 将公布2026年第一季度财务业绩并更新公司动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1193230332","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193230332?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:01","pubTimestamp":1778756490,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. (纳斯达克股票代码:NRXP) 宣布，即将发布其2026年第一季度的财务报告，并将同时提供公司业务进展的最新情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138049174","title":"NRX制药公司获FDA积极学科审评函 仅需微调行政事项","url":"https://stock-news.laohu8.com/highlight/detail?id=1138049174","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138049174?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:02","pubTimestamp":1776855759,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc.（NRX制药公司）近日收到美国食品药品监督管理局（FDA）发出的学科审评函，该函件传递积极信号，仅要求对申报材料进行细微的行政层面调整。\n此次审评结果标志着公司研发项目取得关键进展。监管机构未提出实质性科学问题，凸显了申报资料的质量与完整性。此类审评结果通常预示着后续审批流程可能更为顺畅。\n公司表示将迅速完成FDA要求的行政修改，并继续推进相关申请流程。这一进展为NRX Pharmaceuticals Inc.的核心产品开发路径增添了确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151368808","title":"FDA仿制药办公室表态支持NRX Pharmaceuticals Inc. ANDA于当前审评周期内获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1151368808","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151368808?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:01","pubTimestamp":1776855719,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）仿制药办公室（Office of Generic Drugs）已公开表示，支持NRX Pharmaceuticals Inc.（NRXP）旗下ANDA（简化新药申请）在当前审评周期内获得批准。这一积极表态为该公司关键药物的上市前景增添了显著信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149759692","title":"NRX Pharmaceuticals 推进机器人辅助经颅磁刺激与神经可塑性疗法结合应用于军事和急救人员领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1149759692","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149759692?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:02","pubTimestamp":1776250935,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. 宣布，其结合机器人辅助经颅磁刺激与神经可塑性疗法的研究项目取得重要进展。这项创新技术主要面向军事人员及急救人员群体开发，旨在通过先进的神经调控手段提升心理健康干预效果。该公司正积极推动该疗法的应用拓展，有望为高风险职业人群提供更精准、高效的非侵入式治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196360376","title":"NRX Pharmaceuticals Inc.研发项目将通过旗下NRX Defense Systems部门与Zeta Surgical联合推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1196360376","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196360376?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:02","pubTimestamp":1776250930,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc.宣布，其研发项目将由旗下专注于国防系统研发的NRX Defense Systems部门主导，并与Zeta Surgical公司建立战略合作关系。这一合作标志着双方将在技术研发领域实现资源整合与优势互补。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117019598","title":"NRX Pharmaceuticals（纳斯达克：NRXP）任命Glenn Tyson担任公司首位首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1117019598","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117019598?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:04","pubTimestamp":1776078249,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals（纳斯达克：NRXP）宣布，Glenn Tyson已加入公司，担任其首位首席商务官。这一重要人事任命标志着公司在商业化战略布局上迈出关键一步，将进一步提升其市场拓展与业务发展能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174037465","title":"NRX制药子公司Hope Therapeutics与Emobot达成战略合作 将在介入精神病学网络部署AI抑郁评估工具","url":"https://stock-news.laohu8.com/highlight/detail?id=1174037465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174037465?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:02","pubTimestamp":1774868562,"startTime":"0","endTime":"0","summary":"NRX制药公司旗下子公司Hope Therapeutics宣布与人工智能企业Emobot建立战略合作伙伴关系，计划将其开发的AI驱动型\"抑郁温度计\"评估系统全面整合至介入精神病学诊疗网络。该合作将依托Emobot的人工智能技术平台，通过数据分析模型对患者情绪状态进行量化评估，为临床干预提供精准参考依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119959941","title":"NRX Pharmaceuticals（纳斯达克：NRXP）公布2025财年业绩，聚焦关键监管与商业进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1119959941","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119959941?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:02","pubTimestamp":1774350143,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc.（纳斯达克代码：NRXP）近日披露了2025财年完整财务报告，并重点展示了公司在监管审批与商业化进程中的重大突破。报告期内，公司不仅在核心产品研发上取得实质性进展，还通过战略合作与市场拓展显著提升了行业竞争力。管理层在财报中强调，多项关键临床试验数据已达到预期目标，为后续新药申报奠定了坚实基础。与此同时，公司正积极与全球监管机构沟通，加速推进产品上市流程。在商业化层面，NRX Pharmaceuticals通过优化供应链与扩大市场覆盖，进一步巩固了其在创新疗法领域的领先地位。未来，公司计划持续投入高潜力管线，以应对日益增长的市场需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193457023","title":"NRX Pharmaceuticals Inc. (纳斯达克: NRXP) 将于2026年3月24日公布2025财年全年业绩并举行公司进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1193457023","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193457023?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:08","pubTimestamp":1773918512,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. (纳斯达克: NRXP) 宣布，公司计划于2026年3月24日发布其2025财年全年财务报告。届时，管理层还将同步提供最新的公司运营进展与战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111626318","title":"NRX子公司Hope Therapeutics在佛州棕榈滩开设诊所 提供抑郁症与创伤后应激障碍单日疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1111626318","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111626318?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:03","pubTimestamp":1773054198,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc.（纳斯达克代码：NRXP）旗下子公司Hope Therapeutics宣布，其位于佛罗里达州棕榈滩的诊疗中心正式投入运营。该诊所创新性地推出针对抑郁症及创伤后应激障碍的单日疗程治疗方案，旨在为患者提供高效、集中的医疗服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167387309","title":"NRX Pharmaceuticals（纳斯达克：NRXP）任命Joshua Brown医学及哲学博士为首席医疗创新官","url":"https://stock-news.laohu8.com/highlight/detail?id=1167387309","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167387309?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:02","pubTimestamp":1772452970,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc.（纳斯达克股票代码：NRXP）近日宣布，正式任命Joshua Brown教授担任公司首席医疗创新官一职。Brown教授拥有医学博士及哲学博士学位，其深厚的学术背景与丰富的临床经验将为公司新药研发与创新战略注入强劲动力。此项人事任命彰显了NRX Pharmaceuticals持续强化研发领导力、加速创新疗法开发的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169441002","title":"NRX制药将结合现有临床试验数据与Osmind拟议真实世界数据 申请NRX-100获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1169441002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169441002?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:16","pubTimestamp":1771330590,"startTime":"0","endTime":"0","summary":"NRX制药公司宣布，计划整合其掌握的临床试验数据与Osmind平台提供的拟议真实世界证据，共同向监管机构提交NRX-100的上市申请。这一策略旨在通过传统研究数据与真实临床实践数据的互补，强化该药物治疗方案的论证基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512485964","title":"Nrx Pharmaceuticals, Inc.盘中异动 股价大跌5.15%报2.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512485964","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512485964?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:03","pubTimestamp":1739977417,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时03分，Nrx Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.15%。截至发稿，该股报2.58美元/股，成交量11.7498万股，换手率0.69%，振幅8.72%。Nrx Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。Nrx Pharmaceuticals, Inc.公司简介：NRX Pharmaceuticals Inc 是一家临床阶段的小分子制药公司，开发并计划销售用于治疗中枢神经系统疾病和危及生命的肺部疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219230338a24c02d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219230338a24c02d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":-0.1316},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.2305},{"period":"6month","weight":0.7204},{"period":"1year","weight":0.21},{"period":"ytd","weight":0.3395}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0139},{"period":"3month","weight":0.0385},{"period":"6month","weight":0.0628},{"period":"1year","weight":0.1601},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"NRx Pharmaceuticals, Inc.是于2015年5月20日依照特拉华州法律成立的公司。该公司是一家临床阶段的生物制药公司，该公司通过其全资运营子公司NeuroRx, Inc.开发和分销用于治疗中枢神经系统疾病（包括自杀性抑郁症、慢性疼痛、创伤后应激障碍以及现在的精神分裂症）的新型疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.074525},{"month":2,"riseRate":0.2,"avgChangeRate":-0.102766},{"month":3,"riseRate":0.4,"avgChangeRate":-0.034339},{"month":4,"riseRate":0.4,"avgChangeRate":-0.100305},{"month":5,"riseRate":0.8,"avgChangeRate":0.153649},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.15132},{"month":7,"riseRate":0.333333,"avgChangeRate":0.014345},{"month":8,"riseRate":0.2,"avgChangeRate":-0.14211},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012776},{"month":10,"riseRate":0.6,"avgChangeRate":0.037482},{"month":11,"riseRate":0.4,"avgChangeRate":0.048439},{"month":12,"riseRate":0.6,"avgChangeRate":0.121824}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NRX Pharmaceuticals Inc.(NRXP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NRX Pharmaceuticals Inc.(NRXP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}